Deucravacitinib is a new JAK Inhibitor. It’s approved to treat moderate to severe plaque psoriasis. It works by targeting the Janus kinase enzymes, like JAK1 and JAK2, which are key for certain immune cells to work properly.
This tweak helps control the immune reactions that play a role in psoriasis. Deucravacitinib comes in the form of 6 mg film-coated tablets and the recommended dosage is 6 mg taken once daily. Each bottle has 30 pills, so it’s good for a whole month of treatment, keeping it consistent.
Reviews
There are no reviews yet.